Business
Total Voting Rights update
Total Voting Rights update.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \n \n RNS Number : 6411U\n Shield Therapeutics PLC\n 31 July 2020\n \n \n \n \n Shield Therapeutics plc\n \n \n (\"Shield\" or the \"Group\")\n \n \n \n \n \n Total Voting Rights Update\n \n \n \n \n \n \n London, UK, 31 July 2020: \n \n Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product \n Feraccru\n ®\n /Accrufer\n \n \n ®\n \n \n (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 117,188,657 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\n \n \n \n \n \n The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n \n Shield Therapeutics plc\n \n \n \n \n www.shieldtherapeutics.com\n \n \n \n \n \n \n Tim Watts, Chief Executive Officer\n \n \n \n \n +44 (0)20 7186 8500\n \n \n \n \n \n \n Lucy Bailey, General Counsel and Company Secretary\n \n \n \n +44 (0) 19 1511 8500\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Nominated Advisor and Broker\n \n \n \n \n \n \n \n \n \n Peel Hunt LLP\n \n \n \n \n \n \n \n \n \n James Steel/Dr Christopher Golden\n \n \n \n \n +44 (0)20 7418 8900\n \n \n \n \n \n \n \n \n \n \n Joint Broker\n \n \n \n finnCap Ltd \n \n \n Geoff Nash/Matt Radley/Alice Lane \n \n \n \n \n \n \n \n \n \n \n +44 (0)20 7220 0500\n \n \n \n \n \n \n \n \n \n \n \n \n \n Financial PR & IR Advisor\n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n \n \n +44 (0)20 7933 8780 or \n \n [email protected]\n \n \n \n \n \n \n \n Paul McManus/Lianne Cawthorne\n \n \n \n \n +44 (0)7980 541 893 / +44 (0)7584 391 303\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Shield Therapeutics plc\n \n \n Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Fer...